Role of the Microrna-29 Family in Fibrotic Skin Diseases
| dc.contributor.author | Harmancı, Duygu | |
| dc.contributor.author | Erkan, Erdogan Pekcan | |
| dc.contributor.author | Kocak, Ayse | |
| dc.contributor.author | Akdoğan, Gül | |
| dc.date.accessioned | 2023-06-16T14:41:16Z | |
| dc.date.available | 2023-06-16T14:41:16Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Fibrotic skin diseases are characterized by the accumulation of collagen. The hallmarks of fibrotic skin diseases are unbalanced fibroblast proliferation and differentiation, extracellular matrix production and transforming growth factor- signalling. Numerous studies have investigated the possibility that microRNAs (miRNAs or miRs) are involved in the pathogenesis of certain fibrotic diseases, including skin, heart, lung and liver diseases. miRNAs are a class of small non-coding RNAs, which modify gene expression by binding to target messenger RNA (mRNA) and blocking the translation or inducing the degradation of target mRNA. The biological relevance of miRNAs has been investigated in physiological and pathological conditions, and there is increasing evidence that the miR-29 family is associated with fibrotic diseases. The aim of the present review is to provide an up-to-date summary of current knowledge on the latest developments associated with the miR-29 family and fibrotic skin diseases. | en_US |
| dc.identifier.doi | 10.3892/br.2017.900 | |
| dc.identifier.issn | 2049-9434 | |
| dc.identifier.issn | 2049-9442 | |
| dc.identifier.uri | https://doi.org/10.3892/br.2017.900 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/2587 | |
| dc.language.iso | en | en_US |
| dc.publisher | Spandidos Publ Ltd | en_US |
| dc.relation.ispartof | Bıomedıcal Reports | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | microRNA-29 family | en_US |
| dc.subject | skin | en_US |
| dc.subject | fibrotic skin diseases | en_US |
| dc.subject | function | en_US |
| dc.subject | pathogenesis | en_US |
| dc.subject | Systemic-Sclerosis | en_US |
| dc.subject | Pulmonary-Fibrosis | en_US |
| dc.subject | Liver Fibrosis | en_US |
| dc.subject | Extracellular-Matrix | en_US |
| dc.subject | Hypertrophic Scars | en_US |
| dc.subject | Mir-29 | en_US |
| dc.subject | Expression | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Pathway | en_US |
| dc.subject | Suppression | en_US |
| dc.title | Role of the Microrna-29 Family in Fibrotic Skin Diseases | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Erkan, Erdogan Pekcan/0000-0001-9287-4773 | |
| gdc.author.id | Kocak, Ayse/0000-0002-1510-2937 | |
| gdc.author.id | Kocak, Ayse/0000-0002-1510-2937 | |
| gdc.author.wosid | Erkan, Erdogan Pekcan/GQR-2513-2022 | |
| gdc.author.wosid | Erkan, Erdogan Pekcan/ABI-6822-2020 | |
| gdc.author.wosid | Kocak, Ayse/AAZ-7831-2020 | |
| gdc.author.wosid | Kocak, Ayse/W-3229-2017 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C4 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Harmancı, Duygu; Kocak, Ayse] Dokuz Eylul Univ, Grad Sch Hlth Sci, Dept Mol Med, Hlth Campus,1606 Mithatpasa St, TR-35340 Izmir, Turkey; [Erkan, Erdogan Pekcan] Univ Helsinki, Dept Med Genet, Medicum, Helsinki 00014, Finland; [Akdogan, Gul Guner] Izmir Univ Econ, Sch Med, Dept Med Biochem, TR-35330 Izmir, Turkey | en_US |
| gdc.description.endpage | 604 | en_US |
| gdc.description.issue | 6 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.startpage | 599 | en_US |
| gdc.description.volume | 6 | en_US |
| gdc.description.wosquality | Q3 | |
| gdc.identifier.openalex | W2610765311 | |
| gdc.identifier.pmid | 28584629 | |
| gdc.identifier.wos | WOS:000403893900002 | |
| gdc.index.type | WoS | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 16.0 | |
| gdc.oaire.influence | 3.3764374E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.popularity | 1.7517785E-8 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 1.8077 | |
| gdc.openalex.normalizedpercentile | 0.85 | |
| gdc.opencitations.count | 30 | |
| gdc.plumx.crossrefcites | 13 | |
| gdc.plumx.mendeley | 51 | |
| gdc.plumx.pubmedcites | 23 | |
| gdc.virtual.author | Akdoğan, Gül | |
| gdc.wos.citedcount | 37 | |
| relation.isAuthorOfPublication | 4c485711-f05e-4293-a877-512e03de58f6 | |
| relation.isAuthorOfPublication.latestForDiscovery | 4c485711-f05e-4293-a877-512e03de58f6 | |
| relation.isOrgUnitOfPublication | 4cbb0a74-ee1a-438b-b714-b8ef253df94b | |
| relation.isOrgUnitOfPublication | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 4cbb0a74-ee1a-438b-b714-b8ef253df94b |
Files
Original bundle
1 - 1 of 1
